JP2008504266A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504266A5 JP2008504266A5 JP2007518182A JP2007518182A JP2008504266A5 JP 2008504266 A5 JP2008504266 A5 JP 2008504266A5 JP 2007518182 A JP2007518182 A JP 2007518182A JP 2007518182 A JP2007518182 A JP 2007518182A JP 2008504266 A5 JP2008504266 A5 JP 2008504266A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- trifluoromethyl
- amino
- tetrazol
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- CBURHJABGYUEIY-UHFFFAOYSA-N propan-2-yl 2-(fluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)C)C(CF)CCC2=C1 CBURHJABGYUEIY-UHFFFAOYSA-N 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- KZPNHUVBHNWBAT-UHFFFAOYSA-N propan-2-yl 2-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)C)C(C(F)(F)F)CCC2=C1 KZPNHUVBHNWBAT-UHFFFAOYSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- NGDSOQQNCOUHTC-BVAGGSTKSA-N 2-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2r,4s)-1-(cyclopentylmethyl)-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinolin-4-yl]amino]tetrazol-2-yl]ethanol Chemical compound N1=NN(CCO)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)CC1CCCC1)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NGDSOQQNCOUHTC-BVAGGSTKSA-N 0.000 claims 1
- XPTZGLLXMQHJCS-KNQAVFIVSA-N 2-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2r,4s)-2-ethyl-1-propan-2-yloxycarbonyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinolin-4-yl]amino]tetrazol-2-yl]acetic acid Chemical compound N1=NN(CC(O)=O)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XPTZGLLXMQHJCS-KNQAVFIVSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- AWAZLOZXRYYSGA-RDGATRHJSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-butyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound CCCCN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC(=CC=C3N(C(=O)OC(C)C)[C@H](CC)C2)C(F)(F)F)=N1 AWAZLOZXRYYSGA-RDGATRHJSA-N 0.000 claims 1
- KBYPREHGFGVTAQ-QPPBQGQZSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-propan-2-yltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(C(C)C)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KBYPREHGFGVTAQ-QPPBQGQZSA-N 0.000 claims 1
- ZLZAPHFRAZFJPD-QPPBQGQZSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-propyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound CCCN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC(=CC=C3N(C(=O)OC(C)C)[C@H](CC)C2)C(F)(F)F)=N1 ZLZAPHFRAZFJPD-QPPBQGQZSA-N 0.000 claims 1
- IDEDJVXIRXQBEG-QPPBQGQZSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-tert-butyltetrazol-5-yl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(C(C)(C)C)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 IDEDJVXIRXQBEG-QPPBQGQZSA-N 0.000 claims 1
- LPEYQFKJCVSIJF-QPPBQGQZSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-cyanoethyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CCC#N)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LPEYQFKJCVSIJF-QPPBQGQZSA-N 0.000 claims 1
- JGENTCMORZDZKA-OFNKIYASSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-methoxy-2-oxoethyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CC(=O)OC)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JGENTCMORZDZKA-OFNKIYASSA-N 0.000 claims 1
- VBQYREGCPKREQS-RDGATRHJSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-methylpropyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CC(C)C)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VBQYREGCPKREQS-RDGATRHJSA-N 0.000 claims 1
- RJKSOPSESGGXBX-OFNKIYASSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(cyanomethyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CC#N)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RJKSOPSESGGXBX-OFNKIYASSA-N 0.000 claims 1
- FPZNXSLKZZTRTG-RDGATRHJSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(cyclopropylmethyl)tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CC2CC2)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FPZNXSLKZZTRTG-RDGATRHJSA-N 0.000 claims 1
- LLKCVUADQIALCX-RDGATRHJSA-N propan-2-yl (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-[2-(dimethylamino)ethyl]tetrazol-5-yl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound N1=NN(CCN(C)C)N=C1N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OC(C)C)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LLKCVUADQIALCX-RDGATRHJSA-N 0.000 claims 1
- BDHFDTKPKDVYKM-UHFFFAOYSA-N propan-2-yl 2-methyl-3,4-dihydro-2H-quinoline-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)C)C(C)CCC2=C1 BDHFDTKPKDVYKM-UHFFFAOYSA-N 0.000 claims 1
- KEPUNJAGCBROTF-UHFFFAOYSA-N propan-2-yl 4-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-cyclopropyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C(=O)OC(C)C)C(C2CC2)CC1N(C1=NN(CCN)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KEPUNJAGCBROTF-UHFFFAOYSA-N 0.000 claims 1
- ORJPAXUXLXQBLC-UHFFFAOYSA-N propan-2-yl 4-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-methyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C(=O)OC(C)C)C(C)CC1N(C1=NN(CCN)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ORJPAXUXLXQBLC-UHFFFAOYSA-N 0.000 claims 1
- JCAHFVDJQHMHDN-UHFFFAOYSA-N propan-2-yl 4-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-propan-2-yl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C(=O)OC(C)C)C(C(C)C)CC1N(C1=NN(CCN)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JCAHFVDJQHMHDN-UHFFFAOYSA-N 0.000 claims 1
- NCOZHZDXXZLMEC-UHFFFAOYSA-N propan-2-yl 4-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-propyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C(=O)OC(C)C)C(CCC)CC1N(C1=NN(CCN)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NCOZHZDXXZLMEC-UHFFFAOYSA-N 0.000 claims 1
- QOROJGPZFLVAHW-UHFFFAOYSA-N propan-2-yl 4-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(3-hydroxypropyl)tetrazol-5-yl]amino]-2-methyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylate Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C(=O)OC(C)C)C(C)CC1N(C1=NN(CCCO)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QOROJGPZFLVAHW-UHFFFAOYSA-N 0.000 claims 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58270804P | 2004-06-24 | 2004-06-24 | |
| US62724104P | 2004-11-12 | 2004-11-12 | |
| US66486205P | 2005-03-24 | 2005-03-24 | |
| PCT/US2005/021789 WO2006012093A1 (en) | 2004-06-24 | 2005-06-22 | Compounds and methods for treating dyslipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504266A JP2008504266A (ja) | 2008-02-14 |
| JP2008504266A5 true JP2008504266A5 (enExample) | 2008-08-07 |
Family
ID=35056992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518182A Pending JP2008504266A (ja) | 2004-06-24 | 2005-06-22 | 異脂肪血症を治療するための化合物及び方法 |
| JP2007518296A Expired - Fee Related JP4836945B2 (ja) | 2004-06-24 | 2005-06-23 | 異常脂質血症を治療するための化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518296A Expired - Fee Related JP4836945B2 (ja) | 2004-06-24 | 2005-06-23 | 異常脂質血症を治療するための化合物および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20080269284A1 (enExample) |
| EP (3) | EP1761521A1 (enExample) |
| JP (2) | JP2008504266A (enExample) |
| KR (1) | KR20070041452A (enExample) |
| CN (1) | CN1972932B (enExample) |
| AT (1) | ATE528304T1 (enExample) |
| AU (2) | AU2005267436A1 (enExample) |
| BR (2) | BRPI0512523A (enExample) |
| CA (2) | CA2570688A1 (enExample) |
| CR (1) | CR8831A (enExample) |
| CY (1) | CY1112124T1 (enExample) |
| DK (1) | DK1761522T3 (enExample) |
| EA (2) | EA200700119A1 (enExample) |
| EC (2) | ECSP067095A (enExample) |
| ES (1) | ES2372291T3 (enExample) |
| HR (1) | HRP20110761T1 (enExample) |
| IL (2) | IL180276A0 (enExample) |
| MA (2) | MA28729B1 (enExample) |
| MX (2) | MXPA06014716A (enExample) |
| NO (2) | NO20070470L (enExample) |
| NZ (1) | NZ550978A (enExample) |
| PL (1) | PL1761522T3 (enExample) |
| PT (1) | PT1761522E (enExample) |
| RS (1) | RS52064B (enExample) |
| SI (1) | SI1761522T1 (enExample) |
| WO (2) | WO2006012093A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004023100D1 (de) * | 2003-10-08 | 2009-10-22 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidemie |
| JP2007530550A (ja) * | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| EA200700119A1 (ru) | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2157190B1 (en) * | 2007-05-17 | 2017-05-03 | EA Pharma Co., Ltd. | Method of measuring the activity of lipid-modified enzyme |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| SG10201605304VA (en) * | 2011-07-08 | 2016-08-30 | Novartis Ag | Method of treating atherosclerosis in high triglyceride subjects |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| DK2860175T3 (da) * | 2012-06-11 | 2018-01-29 | Tacurion | Fremgangsmåde til fremstilling af 4,4,7-trifluor-1,2,3,4-tetrahydro-5h-1-benzazepin-forbindelse og intermediat til syntese deraf |
| WO2014012401A1 (zh) * | 2012-07-16 | 2014-01-23 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
| MX369471B (es) * | 2014-02-05 | 2019-11-08 | Dezima Pharma B V | Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares. |
| CN103833637B (zh) * | 2014-03-31 | 2016-01-06 | 武汉武药制药有限公司 | 一种制备依塞曲匹（Evacetrapib）中间体的方法 |
| JP6549735B2 (ja) | 2015-06-09 | 2019-07-24 | アッヴィ・インコーポレイテッド | 核内受容体調節剤 |
| WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
| AU2019318209B2 (en) | 2018-08-10 | 2025-09-25 | Diapin Therapeutics, Llc | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders |
| WO2024249901A2 (en) * | 2023-06-01 | 2024-12-05 | Nico Therapeutics, Inc. | Compounds, compositions, and methods |
| CN117263810B (zh) * | 2023-09-19 | 2026-01-27 | 上海凌凯科技股份有限公司 | 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402506A1 (fr) * | 1977-09-09 | 1979-04-06 | Guelennec Emile Le | Cisaille pour la decoupe de ferrailles de grandes dimensions |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
| CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
| MXPA03009935A (es) * | 2001-04-30 | 2004-01-29 | Pfizer Prod Inc | Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp. |
| US7332514B2 (en) | 2002-08-30 | 2008-02-19 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| WO2004032848A2 (en) | 2002-10-04 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| EP1601655A2 (en) | 2003-03-04 | 2005-12-07 | Takasago International Corporation | Method for producing optically active amines |
| US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
| DE602004023100D1 (de) | 2003-10-08 | 2009-10-22 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidemie |
| JP2007530550A (ja) | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| EA200700119A1 (ru) | 2004-06-24 | 2007-10-26 | Эли Лилли Энд Компани | Соединения и способы лечения дислипидемии |
| US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
-
2005
- 2005-06-22 EA EA200700119A patent/EA200700119A1/ru unknown
- 2005-06-22 WO PCT/US2005/021789 patent/WO2006012093A1/en not_active Ceased
- 2005-06-22 BR BRPI0512523-5A patent/BRPI0512523A/pt not_active Application Discontinuation
- 2005-06-22 US US11/570,540 patent/US20080269284A1/en not_active Abandoned
- 2005-06-22 CA CA002570688A patent/CA2570688A1/en not_active Abandoned
- 2005-06-22 AU AU2005267436A patent/AU2005267436A1/en not_active Abandoned
- 2005-06-22 EP EP05768995A patent/EP1761521A1/en not_active Withdrawn
- 2005-06-22 JP JP2007518182A patent/JP2008504266A/ja active Pending
- 2005-06-22 KR KR1020067027038A patent/KR20070041452A/ko not_active Ceased
- 2005-06-22 MX MXPA06014716A patent/MXPA06014716A/es not_active Application Discontinuation
- 2005-06-23 MX MXPA06014706A patent/MXPA06014706A/es active IP Right Grant
- 2005-06-23 CN CN2005800206855A patent/CN1972932B/zh not_active Expired - Fee Related
- 2005-06-23 AU AU2005258241A patent/AU2005258241B2/en not_active Ceased
- 2005-06-23 JP JP2007518296A patent/JP4836945B2/ja not_active Expired - Fee Related
- 2005-06-23 PL PL05763328T patent/PL1761522T3/pl unknown
- 2005-06-23 RS RS20110559A patent/RS52064B/sr unknown
- 2005-06-23 SI SI200531438T patent/SI1761522T1/sl unknown
- 2005-06-23 NZ NZ550978A patent/NZ550978A/en not_active IP Right Cessation
- 2005-06-23 AT AT05763328T patent/ATE528304T1/de active
- 2005-06-23 HR HR20110761T patent/HRP20110761T1/hr unknown
- 2005-06-23 ES ES05763328T patent/ES2372291T3/es not_active Expired - Lifetime
- 2005-06-23 EP EP05763328A patent/EP1761522B1/en not_active Expired - Lifetime
- 2005-06-23 EA EA200700120A patent/EA012585B1/ru not_active IP Right Cessation
- 2005-06-23 DK DK05763328.1T patent/DK1761522T3/da active
- 2005-06-23 PT PT05763328T patent/PT1761522E/pt unknown
- 2005-06-23 EP EP11184746A patent/EP2479175A1/en not_active Withdrawn
- 2005-06-23 WO PCT/US2005/022389 patent/WO2006002342A1/en not_active Ceased
- 2005-06-23 BR BRPI0512516-2A patent/BRPI0512516A/pt active Search and Examination
- 2005-06-23 US US11/570,542 patent/US7786108B2/en not_active Expired - Fee Related
- 2005-06-23 CA CA2570673A patent/CA2570673C/en not_active Expired - Fee Related
-
2006
- 2006-12-19 EC EC2006007095A patent/ECSP067095A/es unknown
- 2006-12-19 EC EC2006007098A patent/ECSP067098A/es unknown
- 2006-12-22 CR CR8831A patent/CR8831A/es unknown
- 2006-12-24 IL IL180276A patent/IL180276A0/en unknown
- 2006-12-24 IL IL180277A patent/IL180277A/en not_active IP Right Cessation
- 2006-12-29 MA MA29595A patent/MA28729B1/fr unknown
- 2006-12-29 MA MA29596A patent/MA28730B1/fr unknown
-
2007
- 2007-01-24 NO NO20070470A patent/NO20070470L/no not_active Application Discontinuation
- 2007-01-24 NO NO20070468A patent/NO20070468L/no not_active Application Discontinuation
-
2010
- 2010-04-20 US US12/763,344 patent/US20100204207A1/en not_active Abandoned
-
2011
- 2011-11-25 CY CY20111101160T patent/CY1112124T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504266A5 (enExample) | ||
| RU2347778C2 (ru) | Новые антагонисты р2х7 рецепторов, способ их получения, фармацевтическая композиция, способ лечения и применение на их основе | |
| RU2405774C9 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| KR101186386B1 (ko) | Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도 | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2010504346A5 (enExample) | ||
| JP2007538092A5 (enExample) | ||
| RU2007128987A (ru) | 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры | |
| JP2006505543A5 (enExample) | ||
| RU2008126245A (ru) | Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| EP4408529A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| JP2007509057A5 (enExample) | ||
| JP2022522312A (ja) | ピロール化合物 | |
| RU2006146215A (ru) | Производные аминопропанола | |
| RU2009148507A (ru) | Производное тетрагидроизохинолин-1-она или его соль | |
| JP2004525183A5 (enExample) | ||
| RU2401267C2 (ru) | Замещенные производные бензохинолизина | |
| JP2023525359A5 (enExample) | ||
| RU2007116987A (ru) | Новые соединения | |
| RU2006113942A (ru) | Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека | |
| WO2020023710A1 (en) | Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same | |
| JP2007508301A5 (enExample) | ||
| CA2566601A1 (en) | Carboxamido opioid compounds | |
| RU2015113959A (ru) | Индолины |